


1632
File
Nile
11/26/02

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on November 15, 2002

INFORMATION DISCLOSURE
STATEMENT
Examining Group 1632
Patent Application
Docket No. USF-T135
Serial No. 09/435,471

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Anne Marie Baker
Art Unit : 1632
Applicants : Denise R. Cooper, Niketa A. Patel
Serial No. : 09/435,471
Filed : November 8, 1999
For : Glucose-Regulated mRNA Instability Element

RECEIVED

NOV 20 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig

Glenn P. Ladwig
Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08; copies of references cited therein.

H:\USFT135\IDS.pto.doc/DNB/mv